Evidence map›Paper›PMID 41169013›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Two-Stage Cascading Amplification Strategy Based on Zn

Junhua Su, Zhenzhen Liu, Renjie Xiong, Renlong Zhu, Zijin Tong, Yufei Liu, Rui Xiao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Two-Stage Cascading Amplification Strategy Based on ZnAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junhua SuKey Laboratory of Optoelectronic Technology & Systems (Chongqing University) Ministry of Education, Chongqing, 400044, China.
Zhenzhen LiuState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, 100071, China.
Renjie XiongKey Laboratory of Optoelectronic Technology & Systems (Chongqing University) Ministry of Education, Chongqing, 400044, China.
Renlong ZhuState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, 100071, China.
Zijin TongState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, 100071, China.
Yufei LiuKey Laboratory of Optoelectronic Technology & Systems (Chongqing University) Ministry of Education, Chongqing, 400044, China.
Rui XiaoState Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, 100071, China.

Funding

Natural Science Foundation of Chongqing cstc2021jcyj-jqX0014
6 · The paper itself

Abstract

Clostridium difficile is one of the primary causative agents of nosocomial antibiotic-associated diseases. Early detection and prevention are effective strategies to curb disease transmission, which often requires highly sensitive point-of-care testing (POCT) methods. Although lateral flow immunoassay (LFIA) technology-known for its convenience, speed, and cost-effectiveness-has gained prominence in POCT, its application in early screening remains limited due to relatively low sensitivity. Herein, a two-stage cascading enhancement strategy based on reductase-like and peroxidase-like activities of nanozyme to construct a colorimetrically enhanced LFIA platform is proposed. Specifically, Zn

Indexed as

Bacterial ProteinsBacterial ToxinsClostridioides difficileZincColorimetryGoldHumansImmunoassayLimit of DetectionMetal NanoparticlesPoint-of-Care TestingBacterial ProteinsBacterial ToxinsGoldtoxB protein, Clostridium difficileZincbioassayelectronic structureion dopinglateral flow immunoassaysperoxidase mimicWOX

Identifiers

PMID41169013
PMCPMC12806447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.